Welcome to our dedicated page for GlucoTrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on GlucoTrack stock.
GlucoTrack, Inc. (symbol: GCTK) is a pioneering medical device company focused on the innovation and commercialization of non-invasive glucose monitoring devices. Established in 2001, the company aims to improve the quality of life for individuals with diabetes by eliminating the pain and inconvenience associated with traditional glucose monitoring methods. Since its inception, GlucoTrack has been dedicated to developing breakthrough technologies that provide a seamless glucose monitoring experience.
The company’s flagship product, the GlucoTrack® model DF-F, utilizes a unique combination of ultrasound, thermal, and electromagnetic technologies along with a proprietary algorithm to measure glucose levels without the need for painful finger pricks. This device has received CE Mark approval in June 2013 and KFDA approval in March 2016. Currently, the GlucoTrack® model DF-F is marketed across the European Union and South Korea.
In November 2011, GlucoTrack went public, further broadening its scope and capabilities in the medical device industry. The company has completed a successful feasibility study indicating that the non-invasive sensor design has a minimum two-year implant life. An ongoing animal study with an initial prototype system has also shown promising results, demonstrating a straightforward implant procedure and effective functionality.
GlucoTrack, Inc. continues to focus on enhancing its product offerings and expanding its market presence through strategic partnerships and continuous innovation. For the latest updates and information about GlucoTrack, visit the company’s official website or contact their investor relations team at: investors@glucotrack.com.
Glucotrack (Nasdaq: GCTK) has completed a $10.0 million public offering and concurrent private placement. The offering included 2,437,340 shares of common stock and 4,756,900 pre-funded warrants at $1.39 per share. Each share and warrant came with series A and B common warrants exercisable at $1.81 per share. Additionally, the company converted $4.0 million in outstanding secured convertible notes from July 2024 into equity on similar terms. Dawson James Securities acted as the sole placement agent for the public offering.
Glucotrack (Nasdaq: GCTK) announced a $10.0 million public offering of approximately 7,195,000 shares of common stock or pre-funded warrants at $1.39 per unit. Each unit includes series A and B common warrants exercisable at $1.81 per share. Additionally, the company will convert approximately $4.0 million in outstanding secured convertible notes from July 2024 in a concurrent private placement. The offering is expected to close on November 14, 2024, with Dawson James Securities acting as the sole placement agent.
Glucotrack (Nasdaq: GCTK), a medical technology company focusing on diabetes technologies, will participate in the 2024 BioFuture Conference in New York City from October 28-30, 2024. Paul V. Goode, President & CEO, will present on October 29 at 11:00 AM ET, providing an update on the company's continuous blood glucose monitor (CBGM) development.
The BioFuture Conference will explore topics such as quantum computing in biology, alternative financing, AI in healthcare, psychedelics in mental health treatments, and bioethical challenges. Speakers from prominent companies like Regeneron Pharmaceuticals, IBM, and JP Morgan will discuss major trends shaping healthcare's future.
Qualified investors and media can apply for complimentary registration to attend the conference, which will feature over 100 future-focused presentations.
Glucotrack, Inc. (Nasdaq: GCTK) announced that updated preclinical data for its continuous blood glucose monitor (CBGM) will be presented at the 24th Annual Diabetes Technology Meeting from October 15-17, 2024, in Burlingame, California. Mark Tapsak, PhD, Vice President of Sensor Technology, will deliver an oral presentation titled "The Technology Behind Continuous Blood Glucose Monitoring" on October 17.
The company will also present two posters: "In Vivo Evaluation of Novel Long-Term Intravascular Continuous Blood Glucose Monitor in a Chronic Ovine Model" and "Exploratory Study of Continuous Glucose Monitoring in the Epidural Space in Swine". These presentations aim to showcase the CBGM's ability to accurately measure glucose levels without the lag time associated with interstitial glucose and without an on-body wearable, potentially offering a less intrusive approach for people with diabetes.
Glucotrack Inc. (Nasdaq: GCTK), a medical technology company focused on developing novel technologies for diabetes management, has appointed John Ballantyne, PhD, to its Board of Directors. Ballantyne brings over 20 years of experience from Aldevron, a global biotechnology contract development and manufacturing organization he co-founded. As former Chief Science Officer at Aldevron, Ballantyne has extensive experience in healthcare research, innovation, and strategic growth.
Paul Goode, PhD, President and CEO of Glucotrack, expressed confidence that Ballantyne's expertise will be invaluable as the company expands and moves towards commercializing its novel continuous blood glucose monitoring (CBGM) technology. Ballantyne, who holds a Doctorate in Pharmaceutical Sciences, has developed relationships across various biotechnology sectors through investments and advisory roles.
Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on diabetes management, has announced the appointment of Sandie Martha as Vice President of Clinical Operations. With over 20 years of experience in clinical research, Martha brings expertise in leading global clinical trials for glucose monitoring and cardiology. Her role will be important in executing Glucotrack's Clinical Trial Program for their Continuous Blood Glucose Monitor (CBGM).
Martha's extensive background includes leadership positions at Glysens, Dexcom, and Truvian, where she managed various aspects of clinical trials and regulatory submissions. Her appointment is seen as a strategic move to advance Glucotrack's CBGM technology through clinical trials and ultimately bring it to market for millions of people living with diabetes.
Glucotrack Inc. (Nasdaq: GCTK) presented new findings at the ADCES 2024 Annual Conference, revealing strong interest in their innovative Continuous Blood Glucose Monitor (CBGM) concept. The market research study showed that over 50% of surveyed diabetes patients are open to adopting this new technology.
Key features attracting interest include:
- Long-term sensor life (up to 3 years)
- No wearable component
- Real-time blood glucose readings
The study included 757 respondents with intensive insulin therapy, comprising current CGM users (67%), non-users (25%), and ex-users (8%). Glucotrack's CBGM concept aims to address unmet needs in diabetes management, offering a more convenient and less intrusive monitoring solution. The company has made significant clinical progress, completing successful preclinical studies and planning to initiate human clinical trials later this year.
Glucotrack Inc. (Nasdaq: GCTK) announced a poster presentation at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference in New Orleans, LA, from August 9-12, 2024. The poster, titled 'Evaluating Acceptance of a Continuous Blood Glucose Monitor for Insulin-Requiring People with Diabetes', will showcase market research data on the acceptance of Glucotrack's Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes.
CEO Paul V. Goode emphasized the growing interest in expanding glucose monitoring options. The poster session is scheduled for Saturday, August 10, from 12:15 PM to 1:15 PM Eastern time. Glucotrack will make the poster available on their website following the conference presentation.
Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focusing on diabetes management, has secured $4 million in funding from its leading shareholder, John Ballantyne. This funding will support the upcoming First in Human clinical trial for their innovative Continuous Blood Glucose Monitor (CBGM) technology.
CEO Paul V. Goode, PhD, highlighted the company's significant progress in developing their CBGM technology, describing it as a less burdensome approach to glucose monitoring. Ballantyne expressed confidence in the company's potential to deliver strong clinical value to the diabetes community and meaningful value to shareholders, citing the technology's potential to be disruptive in the large and growing diabetes market.
Glucotrack has appointed Andy Balo to its Board of Directors, effective immediately. Balo, a veteran in the diabetes industry, brings decades of experience in regulatory, clinical, and quality domains. He played a key role in shaping Dexcom over 22 years and has coordinated numerous glucose monitoring regulatory submissions and clinical trials globally. Balo has also held leadership roles at St. Jude Medical, Baxter, Pacesetter, and Endocardial Solutions, and has served on several FDA panels. His expertise will be invaluable as Glucotrack advances its continuous blood glucose monitoring technology through clinical and regulatory milestones.
FAQ
What is the current stock price of GlucoTrack (GCTK)?
What is the market cap of GlucoTrack (GCTK)?
What is GlucoTrack, Inc.?
What products does GlucoTrack, Inc. offer?
Where is the GlucoTrack® model DF-F available?
When did GlucoTrack, Inc. go public?
What are the latest achievements of GlucoTrack, Inc.?
How does GlucoTrack® model DF-F work?
What approvals has the GlucoTrack® model DF-F received?
How can I get more information about GlucoTrack, Inc.?
What is the focus of GlucoTrack, Inc.?
Where can I find the latest updates about GlucoTrack, Inc.?
